Valiant Laboratories Limited (NSE:VALIANTLAB)

Market Cap	6.77B +48.9%
Revenue (ttm)	3.06B +89.6%
Net Income	160.14M +12,314.1%
EPS	2.95 +9,817.7%
Shares Out	54.31M
PE Ratio	42.25
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,105
Open	124.00
Previous Close	124.58
Day's Range	124.00 - 127.99
52-Week Range	49.51 - 132.25
Beta	0.92
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Valiant Laboratories

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also manufactures and sells specialty chemicals and chemical intermediates, including chlorophenol derivatives, benzene-based specialty chemicals and other chemical intermediates to agroche...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1980
• Employees: 84
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: VALIANTLAB

Financial Performance

In fiscal year 2026, Valiant Laboratories's revenue was 2.37 billion, an increase of 78.04% compared to the previous year's 1.33 billion. Losses were -32.68 million, 48.5% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 6, 2026

Data Sources Report a data error